Journal
VIRUSES-BASEL
Volume 7, Issue 1, Pages 268-284Publisher
MDPI
DOI: 10.3390/v7010268
Keywords
bacteriophage; CMV; Grp78; AAVP; HSVtk; RGD4C-AAVP/CMV-HSVtk; RGD4C-AAVP/Grp78-HSVtk; glioblastoma
Categories
Funding
- UK Medical Research Council (MRC) [G0701159]
- Brain Tumour Research Campaign (BTRC)
- Medical Research Council [G0701159] Funding Source: researchfish
- MRC [G0701159] Funding Source: UKRI
Ask authors/readers for more resources
Cancer gene therapy expanded and reached its pinnacle in research in the last decade. Both viral and non-viral vectors have entered clinical trials, and significant successes have been achieved. However, a systemic administration of a vector, illustrating safe, efficient, and targeted gene delivery to solid tumors has proven to be a major challenge. In this review, we summarize the current progress and challenges in the targeted gene therapy of cancer. Moreover, we highlight the recent developments of bacteriophage-derived vectors and their contributions in targeting cancer with therapeutic genes following systemic administration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available